Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead.
Randomized clinical trials of neo-adjuvant cisplatin-based combination chemotherapy for locally advanced muscle invasive bladder cancer has shown a survival benefit over cystectomy alone. Pathologic complete response (pT0) after neo-adjuvant chemotherapy is emerging as a potentially important surrogate clinical end point. Future clinical trials incorporating targeted therapies with novel clinical end points may accelerate development of therapeutic strategies for locally advanced muscle invasive bladder cancer. Furthermore, evaluation of molecular markers may further help to stratify patients to a risk adapted approach.
Sawhney
R
R
Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, SC 29425, USA.
Bourgeois
D
D
Chaudhary
U B
UB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000502:physiology; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D019042:Muscle Neoplasms / Q000473:pathology / Q000556:secondary*; D020360:Neoadjuvant Therapy / Q000379:methods*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000188:drug therapy; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D014408:Biomarkers, Tumor